Biofrontera Inc. Common Stock (BFRI)

FairStock Score: 62/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Looking at Biofrontera, I see a small specialty dermatology commercializer, not a wide-moat franchise. It sells Ameluz and lamps for actinic keratosis, with only 84 employees. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $12.0M and net loss was $604,000. That is a sharp improvement from fiscal Q2 2025, the quarter ended 2025-06-30, when revenue was $9.0M and net loss was $5.3M. For FY2025, the year ended 2025-12-31, revenue was $41.7M and net loss was $10.5M; for FY2024, revenue was $37.3M and net loss was $17.8M. Sales are growing and losses are narrowing, but the company has lost money in each of the last four years. The FairStock Lynch category is none for that reason.

In plain English: Biofrontera sells skin treatments for pre-cancerous lesions. The business is growing sales but still losing money and burning cash. At 89 cents a share and a roughly $13 million market value, the price does not look clearly cheap against those weak profits; it looks like a speculative turnaround bet.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer